RT Journal Article
T1 Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
A1 Gutiérrez, Lourdes
A1 Royuela, Ana
A1 Carcereny, Enric
A1 López-Castro, Rafael
A1 Rodríguez-Abreu, Delvys
A1 Massuti, Bartomeu
A1 González-Larriba, José Luis
A1 García-Campelo, Rosario
A1 Bosch-Barrera, Joaquim
A1 Guirado, María
A1 Camps, Carlos
A1 Dómine, Manuel
A1 Bernabé, Reyes
A1 Casal, Joaquín
A1 Oramas, Juana
A1 Ortega, Ana Laura
A1 Sala, Mª Angeles
A1 Padilla, Airam
A1 Aguiar, David
A1 Juan-Vidal, Oscar
A1 Blanco, Remei
A1 Del Barco, Edel
A1 Martínez-Banaclocha, Natividad
A1 Benítez, Gretel
A1 de Vega, Blanca
A1 Hernández, Ainhoa
A1 Saigi, Maria
A1 Franco, Fernando
A1 Provencio, Mariano
K1 EGFR
K1 Long survival
K1 Nomogram
K1 Non-small cell lung cancer
K1 Predictive modeling
AB There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. EGFR mutated stage IIIB and IV NSCLC patients diagnosed between January 2009 and December 2017 included in the Spanish Lung Cancer Group (SLCG) thoracic tumor registry. Long-term survival was defined as being alive 24 months after diagnosis. A multivariable prognostic model was carried out using binary logistic regression and internal validation through bootstrapping. A nomogram was developed to facilitate the interpretation and applicability of the model. 505 of the 961 EGFR mutated patients identified in the registry were included, with a median survival of 27.73 months. Factors associated with overall survival longer than 24 months were: being a woman (OR 1.78); absence of the exon 20 insertion mutation (OR 2.77); functional status (ECOG 0-1) (OR 4.92); absence of central nervous system metastases (OR 2.22), absence of liver metastases (OR 1.90) or adrenal involvement (OR 2.35) and low number of metastatic sites (OR 1.22). The model had a good internal validation with a calibration slope equal to 0.781 and discrimination (optimism corrected C-index 0.680). Survival greater than 24 months can be predicted from six pre-treatment clinicopathological variables. The model has a good discrimination ability. We hypothesized that this model could help the selection of the best treatment sequence in EGFR mutation NSCLC patients.
YR 2021
FD 2021-08-31
LK http://hdl.handle.net/10668/18484
UL http://hdl.handle.net/10668/18484
LA en
DS RISalud
RD Apr 17, 2025